The Schilling test is a unique diagnostic tool used to evaluate a person’s ability to absorb vitamin B12 from their diet. The test was developed in the 1950s by Dr. A.C. Schilling and is still used today to diagnose conditions such as pernicious anemia, which is an autoimmune disorder that affects the body’s ability to absorb vitamin B12. While the Schilling test has been around for decades, there are still some mysteries surrounding it. In this article, we will explore the Schilling test and unlock some of the secrets behind this unique diagnostic tool.
The Schilling test is a medical procedure used to evaluate a person’s ability to absorb vitamin B12 from their diet. The test consists of two parts. The first part is a baseline test, which involves taking a sample of the person’s urine before they consume any vitamin B12. The second part is the post-absorptive test, which involves taking a sample of the person’s urine after they consume a dose of vitamin B12. The results of the test are then compared to determine if the person is able to absorb vitamin B12 from their diet.
The Schilling test works by measuring the amount of vitamin B12 that is absorbed by the body. During the baseline test, a sample of the person’s urine is taken before they consume any vitamin B12. During the post-absorptive test, a sample of the person’s urine is taken after they consume a dose of vitamin B12. The amount of vitamin B12 that is absorbed by the body is then measured and compared to the amount that was consumed. If the amount of vitamin B12 that is absorbed is lower than the amount that was consumed, it indicates that the person is not able to absorb vitamin B12 from their diet.
The Schilling test is primarily used to diagnose pernicious anemia, which is an autoimmune disorder that affects the body’s ability to absorb vitamin B12. Pernicious anemia is caused by an inability of the body to produce intrinsic factor, which is a protein that is necessary for the absorption of vitamin B12. The Schilling test can also be used to diagnose other conditions that affect the absorption of vitamin B12, such as Crohn’s disease, celiac disease, and certain types of gastrectomy surgery.
The Schilling test is a reliable and accurate diagnostic tool that can help diagnose conditions that affect the absorption of vitamin B12. The test is also relatively simple and quick to perform, and does not require any special equipment or preparation. Additionally, the test is relatively inexpensive compared to other diagnostic tests. Finally, the Schilling test is non-invasive and does not involve any radiation, which makes it a safe and effective diagnostic tool.
The Schilling test is a unique diagnostic tool that has been used for decades to diagnose conditions that affect the absorption of vitamin B12. The test is relatively simple to perform, inexpensive, and non-invasive, making it a safe and effective diagnostic tool. While the Schilling test has been around for decades, there are still some mysteries surrounding it. In this article, we have explored the Schilling test and unlocked some of the secrets behind this unique diagnostic tool.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation